The COLLOST brand increased sales by 41% in 2024
The Russian aesthetic brand COLLOST, promoted by the pharmaceutical company Binnopharm Group since 2022, achieved a 41% increase in sales in 2024 compared to 2023. The brand has become the absolute leader in the injectable collagen segment with a 52% share in monetary terms*.
COLLOST, a unique collagen material developed in Russia, has shown strong sales momentum for several years. The expansion of the range and the launch of a new product, COLLOST Micro, have allowed us to increase our audience and occupy the niche left by foreign companies.
The collagen injection products segment, which includes the COLLOST range, will grow by 114% in monetary terms to 2024, becoming one of the key growth drivers in the biorevitalisers and fillers market.
COLLOST is a natural injectable collagen. It promotes the dermal restoration by activating collagenogenesis. Natural collagen-based biomaterial promotes tissue regeneration by stimulating the formation of new collagen fibres. The injectable product is available in eight countries and the range includes a finished product (gel) in syringes of various volumes, sterile type I collagen (powder) in a vial and a post-treatment spray.
* According to the annual national study of the cosmetics market by the company Right to Health.
